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bstract
A residual platelet reactivity (RPR) on antiplatelet therapy in patients with ischemic heart disease (IHD) has been reported to be associated
ith adverse clinical events by some Authors. However, scarce data are present on the clinical parameters associated with this phenomenon.
o study, at our knowledge, was designed with the specific aim to examine the relationship between clinical characteristics and RPR. We
ought to evaluate the clinical and laboratory characteristics associated with RPR in patients with IHD undergoing coronary revascularization
n dual (aspirin plus clopidogrel) antiplatelet therapy. We included in the study 868 patients undergoing a coronary angiography: 386 with
cute coronary syndromes undergoing a primary coronary revascularization and 482 IHD patients scheduled to undergo an elective coronary
ngiography. We measured platelet function by both platelet aggregation with two agonists [0.5 mg/mL arachidonic acid (AA); 2 and 10M
denosine 5′-diphosphate (ADP)] and a point-of-care assay (PFA-100) on venous blood samples collected within 24 h from the end of the
rocedure.
In patients with acute coronary syndromes and elective PCI diabetes is independently associated with RPR [group A: OR = 2.9 (1.5–5.7)
y 10M ADP, OR = 5.3 (1.1–27.8) by PFA-100; group B: OR = 4.0 (1.6–10.0) by 10M ADP]; reduced left ventricular systolic function
OR = 3.7 (2.2–6.5) by AA-PA, OR = 2.7 (1.6–4.6) by PFA-100], chronic use of aspirin [OR = 0.2 (0.1–0.4) by AA-PA, OR = 0.3 (0.2–0.5)
y PFA-100] and loading dose of clopidogrel [OR = 0.2 (0.06–0.5) by 10M ADP] were independent variables significantly associated with
PR in patients undergoing elective PCI. In addition, inflammatory status was found to be significantly associated with RPR in both groups
f patients. These results provide indications for the selection of patients for whom the evaluation of platelet reactivity could be useful.
2007 Published by Elsevier Ireland Ltd.
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. Introduction
Antiplatelet therapy in cardiovascular medicine was
eported to reduce the risk of cardiovascular events by about
5% in a broad category of patients with arterial vascu-
ar disease [1]. Over the last years, a great attention has
een focused on the phenomenon of antiplatelet resistance
hich may be defined as a failure of therapy to prevent
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linical events (i.e. clinical antiplatelet resistance) or as a
ailure of aspirin to inhibit platelet function in ‘in vitro’
ests (i.e. laboratory antiplatelet resistance) [2]. A number
f studies documented the prevalence of laboratory aspirin
3–7] or clopidogrel resistance in different groups of patients
ith ischemic heart disease (IHD) [8–10] and some studies
eported the association with clinical end-points [11–20], but
he clinical parameters associated with antiplatelet resistance
ave not yet been defined.
We sought to evaluate the clinical characteristics associ-
ted with a residual platelet reactivity (RPR) in patients with
HD undergoing percutaneous coronary intervention (PCI)
n dual antiplatelet therapy.
Thus, we measured platelet function by both platelet
ggregation with two agonists (0.5 mg/mL arachidonic acid;
and 10M ADP) and a point-of-care assay (PFA-100) on
enous blood samples collected within 24 h from the end of
he procedure.
We found that diabetes, left ventricular systolic func-
ion, chronic use of aspirin, loading dose of clopidogrel
nd inflammatory status were significantly associated with
latelet reactivity in patients undergoing primary or elective
CI.
. Material and methods
.1. Study population
A total of 868 patients with coronary artery disease and
dmitted to the Division of Cardiology and the Coronary
are Units of the Azienda Ospedaliero-Universitaria Careggi
ere included: 386 with acute coronary syndromes (ACS)
GROUP A) undergoing a primary PCI (STEMI n = 189;
STEMI n = 197) and 482 coronary artery disease patients
GROUP B) scheduled to undergo an elective PCI (385 with
CS in the previous 6–12 months; 97 with stable angina.
inety-one patients had had a previous coronary bypass
urgery). All patients with ACS undergoing primary PCI
eceived a clopidogrel loading dose (93 received 600 mg and
93 received 300 mg) followed by a daily dose of 75 mg.
ne hundred and fifty-three out of 482 patients undergo-
ng an elective PCI received a clopidogrel loading dose of
00 mg. All patients received unfractioned heparin 70 IU/kg
uring the procedure and acetylsalicylic acid (i.v. 500 mg)
ollowed by a daily dose of 100–325 mg by oral route.
hree-hundred and eighty-seven patients were on aspirin and
09 on clopidogrel for at least 1 month before the index
rocedure.
Acute MI was diagnosed as an increase in creatine
inase MB isoenzyme at least twice the upper normal lim-
ts (3.6 ng/mL), and/or elevated cardiac Troponin I (cTnI)
>0.15 ng/mL) levels with at least one of the following: acute
nset of prolonged (≥20 min) typical ischemic chest pain;
T-segment elevation of at least 1 mm in two or more contigu-
us electrocardiographic leads or ST-depression of ≥0.5 mm,
(
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.08 s after the J point in ≥2 contiguous leads, or T waves
nversion >1 mm in leads with predominant R waves. All
atients underwent coronary angiography performed by the
udkins’ technique and PCI if indicated.
Patients were considered to have hypertension if they had
een diagnosed as hypertensives according to the guidelines
f European Society of Hypertension/European Society of
ardiology [21] or were taking antihypertensive drugs. Dys-
ipidemia was defined according to the Third report of the
ational Cholesterol Education Program (NCEP III) [22] and
iabetes in agreement with the American Diabetes Associa-
ion [23].
The exclusion criteria included history of bleeding
iathesis, platelet count ≤ 100,000/mm3, hematocrit 30%,
reatinine ≥ 4.0 mg/dL, and glycoprotein (Gp) IIb/IIIa
nhibitors use.
Informed written consent was obtained from all patients
nd the study was approved by the local Ethical Review
oard.
.2. Experimental procedure
Venous blood samples anticoagulated with 0.129 M
odium citrate (ratio 9:1) were taken from each patient after
CI (15–24 h). The PFA-100 device (Dade-Behring®) was
sed to measure platelet function at high shear conditions
n whole citrated blood. The method determines the time
o occlusion of an aperture in a membrane coated with
ollagen and epinephrine (CT/EPI). Two hundred control
amples were run to determine normal reference laboratory
alues [CT/EPI: mean ± S.D. 144.1 ± 29.5; median (range)
42 (89–204) s]. The coefficient of variation was 8.4% [7].
Whole-blood specimens were centrifuged for 10 min at
50 × g to obtain platelet-rich plasma (PRP). After transfer-
ing into plastic tubes, the remaining blood was centrifuged at
000 × g for 3 min to obtain platelet poor plasma (PPP). PRP
as stimulated with 2 and 10M ADP (Mascia Brunelli,
ilan, Italy) and with 0.5 mg/mL arachidonic acid (AA)
Sigma–Aldrich, Milan, Italy) using a APACT 4 aggregome-
er (Helena Laboratories Italia s.p.a., Milan, Italy). The 100%
ine was set using PPP and the 0% baseline established
ith PRP (adjusted from 18 × 109/L up to 30 × 109/L). As
reviously described, platelet aggregation (PA) (according
o Born’s method) was evaluated considering the maximal
ercentage of platelet aggregation in response to different
timuli (ADP-PA and AA-PA) after 10 min. The coefficient
f variation of AA-LTA and ADP-LTA were 5.8% and 6.8%
espectively [7].
.3. Residual platelet reactivity
We defined patients with ‘residual platelet reactivity’
RPR) those with platelet aggregation by AA > 20% [11]
nd/or ADP (2 and 10mol) above 70% [24,25] and/or those
ith values of CT/EPI by PFA-100 below the 90th percentile
f controls (203 s).
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.4. Statistical analysis
Statistical analysis was performed with SPSS (Statistical
ackage for Social Sciences, Chicago, USA) software for
indows (Version 11.5). Values are presented either as geo-
etric mean (95% confidence intervals). As the parameters
nvestigated had a non-gaussian distribution, log-transformed
alues for leukocyte count and erythrocyte sedimentation rate
ESR) were used in the analyses, and back transformed for
ata presentation. The chi-square test for unpaired data was
sed for comparisons between single groups. To perform the
ultivariate analysis, logistic regression was used with RPR
s the dependent variable and with the parameters differently
p < 0.20) distributed between patients with and without RPR
s the independent variables. Clinical characteristics were
ncluded in the logistic regression analysis in a model in
hich each routinely laboratory parameter (leukocytes, ESR)
as added separately as continuous variable. All odds ratios
OR) are given with their 95% confidence interval. All prob-
bility values are two-tailed, with values of less than 0.05
onsidered statistically significant.
. Results
.1. Residual platelet reactivity by arachidonic acid
nduced aggregation (AA-PA)
GROUP A: RPR was found in 163/386 (42.2%)
atients and was significantly (p < 0.05) more prevalent in
TEMI (93/189 = 49.2%) patients with respect to NSTEMI
70/197 = 35.5%).
Age, diabetes, percentage of patients receiving 100 or
25 mg/die of aspirin, leukocyte count and ESR were sig-
ificantly different between patients with RPR and patients
ithout RPR (Table 1).
At the logistic regression analysis, adjusted for all poten-
ial confounders, leukocyte count and ESR were significant
l
c
c
(
able 1
linical and laboratory characteristics according to platelet reactivity by AA-PA
GROUP A (n = 386)
With RPR (n = 163) Without RPR (n = 223)
ge 70.2 (68.2–72.1) 66.8 (65.1–68.5)
ex (M/F) 110/53 166/57
moking habit (%) 44.2 49.5
ypertension (%) 62.0 67.1
iabetes (%) 31.3 22.2
yslipidemia (%) 25.3 29.5
eripheral artery disease (%) 12.5 7.6
trial fibrillation (%) 16.2 14.3
hronic use of aspirin (%) 20.7 26.6
jection fraction ≤ 40% (%) 47.8 43.3
00 mg aspirin (%) 11.6 25.7
25 mg aspirin (%) 88.4 73.3
eukocytes (×109/L) 11749 (10965–12303) 10000 (9550–10471)
SR (mm/h) 39.8 (35.5–44.7) 28.2 (25.7–30.9)
ata are expressed as % or as geometric mean (95%CI).is 195 (2007) e217–e223 e219
nd independent predictors of RPR detected by AA-PA
Fig. 1).
GROUP B: RPR was found in 110/482 (22.8%) patients
Table 1).
Age, diabetes, chronic use of aspirin, percentage of
atients receiving 100 or 325 mg/die, leukocyte count and
SR were significantly different between patients with RPR
nd patients without RPR (Table 1).
At the logistic regression analysis, adjusted for all
otential confounders, reduced left ventricular systolic func-
ion, chronic use of aspirin and ESR were significant
nd independent predictors of RPR detected by AA-PA
Fig. 2).
.2. Residual platelet reactivity by aggregation induced
y ADP
As the 54 patients found with RPR by 2M ADP had RPR
lso by 10M ADP, we report below the results obtained with
0M ADP.
GROUP A: RPR was found in 99/386 (25.6%) patients
nd was significantly (p < 0.001) more prevalent in STEMI
61/189 = 32.2 %) patients with respect to NSTEMI
38/197 = 19.2%).
Diabetes, reduced left ventricular systolic function
EF ≤ 40%), percentage of patients treated with a loading
ose of 600 mg, leukocyte count and ESR significantly dif-
ered according to RPR (Table 2).
At the logistic regression analysis, adjusted for all
otential confounders, diabetes and leukocyte count were
ignificant and independent predictors of RPR detected by
0M ADP-PA (Fig. 1).
GROUP B: RPR was found in 93/482 (19.2%) patients
Table 2). Diabetes, dyslipidemia, reduced left ventricu-
ar systolic function (EF ≤ 40%), percentage of patients on
lopidogrel treatment prior to the index procedure, leuko-
yte count and ESR significantly differed according to RPR
Table 2).
p-value GROUP B (n = 482) p-value
With RPR (n = 110) Without RPR (n = 372)
0.001 69.5 (67.6–71.5) 67.2 (66.1–68.2) 0.003
ns 87/23 281/91 ns
ns 47.1 45.6 ns
ns 72.3 67.9 ns
0.03 28.8 17.0 0.007
ns 15.6 22.2 ns
ns 27.3 26.1 ns
ns 15.7 14.5 Ns
ns 39.4 67.9 0.0001
ns 50 21.7 0.0001
0.001 65.2 85.5 0.0001
0.001 34.8 14.5 0.0001
0.0001 8128 (7586–8317) 7244 (7079–7413) 0.0001
0.006 25.7 (22.9–29.5) 17.4 (16.2–29.5) 0.0001
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lig. 1. Independent risk factors for RPR in ACS patients (GROUP A, n = 3
istributed between patients with and without RPR were included as indep
leukocyte count, ESR) was added separately as a continuous variable.
At the logistic regression analysis, adjusted for all poten-
ial confounders, diabetes and a 600 mg loading dose of
lopidogrel were significant and independent predictors of
PR detected by 10M ADP-PA (Fig. 2).
Dual RPR (by AA-PA and 10M ADP-PA) was observed
n 122/868 (14%) patients [77/386 (19.9%) of GROUP A and
5/482 (9.3%) of GROUP B].
At multiple logistic regression analysis, diabetes was the
nly clinical characteristic which significantly predicted the
resence of dual RPR with respect to RPR only by AA or
0M ADP both in group A [OR: 2.8 (95%CI 1.3–6.3),
< 0.01] and group B [OR: 2.4 (95%CI 1.1–6.2), p < 0.05].
The prevalence of RPR by AA-PA was significantly
p < 0.0001) higher in patients with RPR by 10M ADP-
A [121/192 (63%)] with respect to those without RPR by
f
l
p
ig. 2. Independent risk factors for RPR in patients undergoing elective PCI (GRO
ifferently (p < 0.20) distributed between patients with and without RPR were incl
aboratory parameter (leukocyte count, ESR) was added separately as a continuousthe logistic regression analysis clinical characteristics differently (p < 0.20)
and dichotomous variables in a model in which each laboratory parameter
0M ADP-PA [154/670 (23%)]. The prevalence of RPR
y 10M ADP-PA was significantly (p < 0.0001) higher in
atients with RPR by AA-PA [114/271 (42%)] with respect
o those without RPR by AA-PA [63/597 (10.6%)].
.3. Residual platelet reactivity by PFA-100
GROUP A: RPR was found in 151/386 (39.1%)
atients and was significantly (p < 0.05) more prevalent in
TEMI (87/189 = 46%) patients with respect to NSTEMI
64/197 = 32.4%).Hypertension, diabetes, reduced left ventricular systolic
unction (EF ≤ 40%), chronic use of aspirin, dose of aspirin,
eukocyte count and ESR significantly differed in RPR
atients with respect to patients without RPR (Table 3).
UP B, n = 482). In the logistic regression analysis, clinical characteristics
uded as independent and dichotomous variables in a model in which each
variable.
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Table 2
Clinical and laboratory characteristics according to platelet reactivity by 10M ADP-PA
GROUP A (n = 386) p-value GROUP B (n = 482) p-value
With RPR (n = 99) Without RPR (n = 287) With RPR (n = 93) Without RPR (n = 389)
Age 68.3 (65.7–70.8) 68.3 (66.9–69.8) ns 68.4 (66.2–70.6) 67.7 (66.6–68.8) ns
Sex (M/F) 69/30 206/81 ns 70/23 294/95 ns
Smoking habit (%) 45.6 48.1 ns 40.5 47.3 ns
Hypertension (%) 63.6 64.7 ns 64.5 70.2 ns
Diabetes (%) 44.3 20.6 0.0001 34.2 16.6 0.001
Dyslipidemia (%) 25.0 28.5 ns 13.4 22.4 0.04
Peripheral artery disease (%) 13.9 7.8 ns 24.6 27.6 ns
Atrial fibrillation (%) 15.2 14.8 ns 14.4 15.8 ns
Previous use of clopidogrel (%) 4.4 7.7 ns 28.9 41.8 0.02
Ejection fraction ≤ 40% (%) 61.2 41.0 0.003 38.3 26.0 0.04
Leukocytes (×109/L) 12882 (12023–13804) 10000 (9550–10471) 0.0001 8318 (7762–8709) 7244 (7079–7413) 0.0001
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DSR (mm/h) 45.7 (39.8–52.5) 29.5 (26.9–31
ata are expressed as % or as geometric mean (95%CI).
At the logistic regression analysis, adjusted for all
otential confounders, diabetes and leukocyte count were
ignificant and independent predictors of RPR detected by
FA-100 (Fig. 1).
GROUP B: RPR was found in 114/482 (23.6%) patients
Table 3 1). Smoking habit, reduced left ventricular systolic
unction (EF ≤ 40%), chronic use of aspirin, percentage of
atients taking 100 mg/die, leukocyte count and ESR signif-
cantly differed according to RPR (Table 3).
At the logistic regression analysis, adjusted for all poten-
ial confounders, reduced left ventricular systolic function,
hronic use of aspirin and smoking habit were significant
nd independent predictors of RPR detected by PFA-100
Fig. 2).. Discussion
This study demonstrates that a number of clinical parame-
ers are independent predictors of RPR on antiplatelet therapy
r
h
s
d
able 3
linical and laboratory characteristics according to platelet reactivity by PFA-100
GROUP A (n = 386)
With RPR (n = 151) Without RPR (n = 235)
ge 68.1 (66.1–70.1) 67.7 (66.6–68.8)
ex (M/F) 113/38 165/70
moking habit (%) 50 46.2
ypertension (%) 68.5 59.4
iabetes (%) 33.8 21.7
yslipidemia (%) 29.3 25.6
eripheral artery disease (%) 10.9 8.8
trial fibrillation (%) 16.0 14.3
hronic use of aspirin (%) 18.1 28.2
jection fraction ≤ 40% (%) 53.0 40.7
00 mg aspirin (%) 5.6 26.0
25 mg aspirin (%) 94.4 74.0
eukocytes (×109/L) 11749 (11220–12589) 10000 (9550–10716)
SR (mm/h) 39.8 (35.5–44.6) 29.5 (26.9–32.3)
ata are expressed as % or as geometric mean (95%CI).0.0001 23.9 (20.9–28.2) 18.2 (17.0–19.5) 0.0001
n patients with coronary artery disease undergone primary or
lective PCI. In particular, diabetes is independently associ-
ted with RPR (by ADP-PA and PFA-100) in both groups of
atients; reduced left ventricular systolic function, diabetes,
hronic use of aspirin and loading dose of clopidogrel, but
ot AF, were the independent variables significantly associ-
ted with RPR (by different methods and agonists) in patients
ndergoing elective PCI.
Diabetes is a condition known to be associated with an
ncreased platelet function which may account for the per-
istent platelet reactivity despite dual antiplatelet therapy
26]. At present, it is still under debate whether enhanced
latelet activation is merely a consequence of more prevalent
therosclerotic lesions or reflects the influence of the accom-
anying metabolic disturbances on platelet biochemistry and
unction. The present study does not allow to evaluate the
ole of metabolic alterations for RPR in high-risk ischemic
eart disease patients. However, many in vitro and in vivo
tudies point to a role of platelets in the early phases of the
iabetic disease [27].
p-value GROUP B (n = 482) p-value
With RPR (n = 114) Without RPR (n = 368)
0.005 68.7 (67.0–70.3) 67.8 (66.0–70.1) 0.005
ns 89/25 275/93 ns
ns 56.4 41.9 0.007
0.05 70.2 65.3 ns
0.009 23.7 18.5 ns
ns 21.3 20.1 ns
ns 22.6 28.1 ns
ns 15.7 14.3 ns
0.02 40.7 66.4 0.0001
0.03 43.9 23.3 0.0001
0.0001 63.0 84.5 0.0001
0.0001 37.0 15.5 0.0001
0.0001 7762 (7586–8318) 7244 (7079–7586) 0.006
0.0001 22.4 (19.5–25.7) 18.2 (16.9–19.5) 0.005
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A novel finding of the present study is related to the
ocumented association between reduced left ventricular
unction and RPR. Platelet abnormalities in chronic heart
ailure have been well described: heart failure patients have
ncreased whole blood aggregation, platelet-derived adhe-
ion molecules, higher mean platelet volume and soluble
-selectin [28]. Therefore, also in this setting, an increased
latelet reactivity may be hypothesized to be the mecha-
ism leading to a higher prevalence of RPR. The frequent
ersistence of platelet activation in heart failure patients on
ntiplatelet agents may have a role for the results of two
ecent trials, the WASH [29] and WATCH [30] trials which
id not show any difference in mortality in patients treated
ith aspirin.
In our patients, chronic use of aspirin and clopidogrel was
ssociated with a lower prevalence of persistent hyperacti-
ated platelets. This finding is apparently in contrast with data
emonstrating that a long-term treatment with aspirin is asso-
iated with a progressive reduction in platelet sensitivity to
ntiplatelet therapy [31]. In our study, the majority of patients
ndergoing elective PCI were patients with a previous ACS
cheduled to undergo a coronary angiography after 6 months
r 1 year, all on antiplatelet therapy. Therefore, the ‘apparent
rotective’ effect of chronic use of aspirin and clopidogrel on
he occurrence of RPR might have been determined by the
act that the majority of these patients were stable, i.e. with
reduced platelet reactivity with respect to ACS patients.
Furthermore, at our knowledge, this is the first study which
ocuments an association between RPR and routinary inflam-
atory markers; interestingly they remained independently
ssociated with RPR in ACS patients and in elective PCI,
uggesting the possible role of other blood cells, such as
eukocytes, in modulating the effect of antiplatelet therapy
n platelet reactivity (as we previously demonstrated for red
lood cells [32]).
Accumulating evidence supports a central role for inflam-
ation in atherosclerosis, with ACS as the principle
linical expression [33]. Platelets represent an important
inkage between inflammation, thrombosis, and atherogen-
sis. Inflammation is characterized by interactions among
latelets, leukocytes and endothelial cells [34]. When acti-
ated, platelets coaggregate with circulating leukocytes [35].
nce adherent to the vascular wall, platelets also provide a
ticky surface to recruit leukocytes to the vessel wall [36].
The measurement of circulating platelet monocyte aggre-
ates would have provided a further insight into the
echanisms involved in the different response to antiplatelet
rugs.
Another issue to be underlined is the possible influence
f ex vivo platelet activation on platelet reactivity results
btained by platelet-rich plasma aggregometry. Validation of
ethods non-sensitive to ex vivo platelet activation is ongo-ng, even though a relationship between platelet reactivity
ndex and ADP-induced PA has been reported [37].
A relevant finding of the present study is related to patients
ith RPR by both AA-PA and ADP-PA. We found that,is 195 (2007) e217–e223
ccording to a previous study on a small number of patients
38], RPR by AA-PA is associated with a significantly higher
isk of RPR also by ADP-PA (42% versus 10.6%) and that
PR by ADP-PA is associated with a significantly higher
isk of RPR by AA-PA (63.4% versus 23%). AA-PA changes
re mainly influenced by the inhibition of the thromboxane
ynthesis and ADP-PA is sensitive to the inhibition of ADP
eceptors, both P2Y1 and P2Y12. However, it was demon-
trated the role of the P2Y12 receptor, target of clopidogrel,
s a functional regulator of thromboxane A2 generation con-
equent to protein-activated receptor stimulation [39] and,
onversely, the fact that ADP- and collagen-induced platelet
ggregation are affected to some extent by aspirin [40]. There-
ore, the finding of an elevated prevalence of dual RPR may
e result from a hyperstimulated state of platelets, not ade-
uately blunted by aspirin and clopidogrel. Furthermore, the
on negligible number of patients with a dual RPR (both
y AA-PA and ADP-PA) identifies a group of patients with a
elevant platelet reactivity for whom different antithrombotic
trategies – higher dosage or a change in the pharmacologi-
al agent – might be indicated. We have identified diabetes as
he characteristic significantly associated with the presence
f dual RPR, underscoring that diabetic patients with IHD
ndergoing PCI are at higher risk of developing a prothrom-
otic condition. As in the last years, a number of studies have
emonstrated an association between RPR and an adverse
rognosis, these results underline the possible usefulness of
valuating platelet reactivity in high-risk patients with dia-
etes and reduced left ventricular systolic function for whom
t may be indicated a carefully ‘tailored’ antithrombotic ther-
py.
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